急性复发性心包炎:从病理生理到新治疗策略
急性特发性或病毒性心包炎通常良性但易复发,其发病与IL-1介导的自身炎症反应及自身抗体/自身反应性T细胞参与的自身免疫反应相关。现行指南推荐阿司匹林/非甾体抗炎药联合秋水仙碱6个月,难治性病例可用低剂量皮质类固醇或免疫抑制剂但疗效有限。越来越多的证据支持IL-1受体拮抗剂(如阿那白滞素)有效且安全,但需更大前瞻性试验评估其地位。
要点
- 复发性心包炎与IL-1介导的自身炎症及自身免疫机制相关。
- 指南推荐NSAIDs联合秋水仙碱6个月治疗复发性心包炎。
- IL-1受体拮抗剂显示良好疗效与安全性,但需进一步研究。
核心结论
- IL-1受体拮抗剂在复发性心包炎治疗中显示良好疗效和安全性,但其治疗地位需更大前瞻性试验评估。
研究设计与样本
- 综述性文章,汇总回顾性研究、一项随机安慰剂对照研究及大型国际真实世界注册研究数据。
主要发现
- 抗心肌或抗闰盘自身抗体与更多复发次数和住院相关。
- 阿那白滞素在多项回顾性研究、一项随机安慰剂对照研究及真实世界注册研究中显示良好疗效和安全性。
- 卡那奴单抗和利洛纳塞等其它IL-1受体拮抗剂显示有希望的结果。
关键数值与推荐
- 指南推荐复发性心包炎使用阿司匹林/非甾体抗炎药数周联合秋水仙碱6个月。
- 难治性病例可考虑低剂量皮质类固醇或免疫抑制剂,但疗效有限。
临床怎么用
- 复发性心包炎应按指南使用NSAIDs联合秋水仙碱6个月。
- 难治性病例可考虑IL-1受体拮抗剂,但需权衡证据与长期安全性。
局限性
- IL-1受体拮抗剂在治疗算法中的位置需更大前瞻性临床试验验证,并评估安全性、成本效益和长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute idiopathic or so-called viral pericarditis is a frequent and usually benign disease, although recurrences are frequent. Data strongly suggest the presence of underlying autoinflammatory and/or autoimmune disorders. It has been reported that there is an inflammatory response of the innate immune system typical of 'autoinflammatory diseases', predominantly mediated by interleukin-1 (IL-1). This may result from the activation of the inflammasome by a cardiotropic virus or a non-specific agent. The inflammatory response of the adaptive immune system, typical of 'autoimmune diseases'-mainly mediated by autoantibodies or autoreactive T lymphocytes-seems also involved as anti-heart or anti-intercalated disk autoantibodies were associated with a higher number of recurrences and hospitalisations. Current guidelines recommend that aspirin/non-steroidal anti-inflammatory drugs for a few weeks should be associated to colchicine for 6 months in recurrent pericarditis. In refractory cases, low-dose corticosteroids or immunosuppressive drugs have been proposed with limited efficacy. Growing evidences suggest a place of IL-1 receptor antagonists in the treatment of recurrent pericarditis. Many retrospective studies, one recent randomised placebo-controlled study and data of a real-life large international registry showed the good efficacy of anakinra with a good safety profile. Other IL-1 receptor antagonists showed promising results (canakinumab, rilonacept). However, IL-1 receptor antagonists' position in the treatment algorithm of recurrent pericarditis needs further evaluation in larger prospective clinical trials to replicate initial findings as well as to assess safety, cost-effectiveness and long-term efficacy.
引用
- Cacoub P, Marques C. Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. Heart. 2020. PMID: 32238419. doi:10.1136/heartjnl-2019-316481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。